会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Methods for assessing risk for cardiac dysrythmia in a human subject
    • 评估人类受试者心脏失血风险的方法
    • US07306911B2
    • 2007-12-11
    • US10475452
    • 2002-04-22
    • Louis PtacekYing-Hui Fu
    • Louis PtacekYing-Hui Fu
    • C12Q1/68C12P19/34C07H21/02C07H21/04
    • C12Q1/6883C12Q2600/156
    • The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.
    • 本发明涉及用于评估患者发展潜在致命性心脏心律失常并用于诊断安徒生综合征的风险的方法。 获得来自患者的组织样品,并分离样品的DNA或蛋白质。 从DNA和蛋白质分离物可以获得KCNJ2基因或Kir2.1多肽的序列。 与Wile型序列相比,可以筛选KCNJ2基因或Kir2.1,以进行改变。 KCNJ2基因或Kir2.1多肽拷贝的改变表明患者发生心脏性心律失常的风险很高,可以诊断为安徒生综合征。 与野生型序列相比,本发明还涉及具有一个或多个改变的分离的核酸分子。
    • 2. 发明申请
    • Methods for assessing risk for cardiac dysrythmia in a human subject
    • 评估人类受试者心脏失血风险的方法
    • US20050175995A1
    • 2005-08-11
    • US10475452
    • 2002-04-22
    • Louis PtacekYing-Hui Fu
    • Louis PtacekYing-Hui Fu
    • C12Q1/68
    • C12Q1/6883C12Q2600/156
    • The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.
    • 本发明涉及用于评估患者发展潜在致命性心脏心律失常并用于诊断安徒生综合征的风险的方法。 获得来自患者的组织样品,并分离样品的DNA或蛋白质。 从DNA和蛋白质分离中可以获得KCNJ2基因或Kir2.1多肽的序列。 与Wile型序列相比,可以筛选KCNJ2基因或Kir2.1,以进行改变。 KCNJ2基因或Kir2.1多肽拷贝的改变表明患者发生心脏性心律失常的风险很高,可以诊断为安徒生综合征。 与野生型序列相比,本发明还涉及具有一个或多个改变的分离的核酸分子。
    • 3. 发明申请
    • Methods for assessing risk for cardiac dysrythmia in a human subject
    • 评估人类受试者心脏失血风险的方法
    • US20080220430A1
    • 2008-09-11
    • US11981388
    • 2007-10-30
    • Louis PtacekYing-Hui Fu
    • Louis PtacekYing-Hui Fu
    • C12Q1/68
    • C12Q1/6883C12Q2600/156
    • The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.
    • 本发明涉及用于评估患者发展潜在致命性心脏心律失常并用于诊断安徒生综合征的风险的方法。 获得来自患者的组织样品,并分离样品的DNA或蛋白质。 从DNA和蛋白质分离物可以获得KCNJ2基因或Kir2.1多肽的序列。 与Wile型序列相比,可以筛选KCNJ2基因或Kir2.1,以进行改变。 KCNJ2基因或Kir2.1多肽拷贝的改变表明患者发生心脏性心律失常的风险很高,可以诊断为安徒生综合征。 与野生型序列相比,本发明还涉及具有一个或多个改变的分离的核酸分子。
    • 4. 发明申请
    • Mass 1 gene, a target for anticonvulsant drug development
    • Mass 1基因,抗惊厥药物开发的目标
    • US20050015822A1
    • 2005-01-20
    • US10912280
    • 2004-08-04
    • Louis PtacekH. WhiteYing-Hui FuShana Skradski
    • Louis PtacekH. WhiteYing-Hui FuShana Skradski
    • C07K14/47C12P21/04A01K67/027C12N5/06
    • C07K14/47A01K2217/05A01K2217/075C12N2517/02
    • The present invention relates to a novel gene which is associated with audiogenic seizures in mice. The gene is known as the Monogenic Audiogenic Seizure-susceptible gene or mass1. The product of the mass1 gene is designated MASS1. Nucleic acid molecules that encode for MASS1 have been identified and purified. The sequence of murine mass1 can be found at SEQ ID NO: 1, and the sequence of human mass1 can be found at SEQ ID NO: 3. Mammalian genes encoding a MASS1 protein are also provided. The invention also provides recombinant vectors comprising nucleic acid molecules that code for a MASS1 protein. These vectors can be plasmids. In certain embodiments, the vectors are prokaryotic or eukaryotic expression vectors. The nucleic acid coding for MASS1 can be linked to a heterologous promoter. The invention also relates to transgenic animals in which one or both alleles of the endogenous mass1 gene is mutated.
    • 本发明涉及与小鼠中的听觉发作相关的新基因。 该基因被称为单因子感觉性发作敏感基因或质量1。 mass1基因的产物命名为MASS1。 编码MASS1的核酸分子已被鉴定和纯化。 鼠群1的序列可以在SEQ ID NO:1中找到,并且人质粒1的序列可以在SEQ ID NO:3中找到。还提供了编码MASS1蛋白的哺乳动物基因。 本发明还提供了包含编码MASS1蛋白的核酸分子的重组载体。 这些载体可以是质粒。 在某些实施方案中,载体是原核或真核表达载体。 编码MASS1的核酸可以与异源启动子连接。 本发明还涉及转基因动物,其中内源mass1基因的一个或两个等位基因被突变。
    • 6. 发明授权
    • Mass1 gene, a target for anticonvulsant drug development
    • Mass1基因,抗惊厥药物开发的目标
    • US06794187B2
    • 2004-09-21
    • US10220587
    • 2002-09-03
    • Louis J. PtacekH. Steve WhiteYing-Hui FuShana Skradski
    • Louis J. PtacekH. Steve WhiteYing-Hui FuShana Skradski
    • C12N516
    • C07K14/47A01K2217/05A01K2217/075C12N2517/02
    • The present invention relates to a novel gene which is associated with audiogenic seizures in mice. The gene is known as the Monogenic Audiogenic Seizure-susceptible gene or mass1. The product of the mass1 gene is designated MASS1. Nucleic acid molecules that encode for MASS1 have been identified and purified. The sequence of murine mass1 can be found at SEQ ID NO: 1, and the sequence of human mass1 can be found at SEQ ID NO: 3. Mammalian genes encoding a MASS1 protein are also provided. The invention also provides recombinant vectors comprising nucleic acid molecules that code for a MASS1 protein. These vectors can be plasmids. In certain embodiments, the vectors are prokaryotic or eukaryotic expression vectors. The nucleic acid coding for MASS1 can be linked to a heterologous promoter. The invention also relates to transgenic animals in which one or both alleles of the endogenous mass1 gene is mutated.
    • 本发明涉及与小鼠中的听觉发作相关的新基因。 该基因被称为单因子感觉性发作敏感基因或质量1。 mass1基因的产物命名为MASS1。 编码MASS1的核酸分子已被鉴定和纯化。 鼠群1的序列可以在SEQ ID NO:1中找到,并且人质粒1的序列可以在SEQ ID NO:3中找到。还提供了编码MASS1蛋白的哺乳动物基因。 本发明还提供了包含编码MASS1蛋白的核酸分子的重组载体。 这些载体可以是质粒。 在某些实施方案中,载体是原核或真核表达载体。 编码MASS1的核酸可以与异源启动子连接。 本发明还涉及转基因动物,其中内源mass1基因的一个或两个等位基因被突变。